The Experts below are selected from a list of 267 Experts worldwide ranked by ideXlab platform
Takao Koike - One of the best experts on this subject based on the ideXlab platform.
-
Transplantation-associated thrombotic microangiopathy after steroid pulse therapy for Polyserositis related to graft-versus-host disease.
Clinical and experimental nephrology, 2010Co-Authors: Yasunobu Ishikawa, Saori Nishio, Hiroaki Sasaki, Risshi Kudo, Hideki Goto, Masanori Ito, Akira Suzuki, Yuichiro Fukazawa, Toshio Mochizuki, Takao KoikeAbstract:Transplantation-associated thrombotic microangiopathy (TA-TMA) is a rare but devastating syndrome that occurs in allogeneic hematopoietic stem cell transplant recipients, and is associated with a variety of transplantation-related factors, including conditioning regimens, immunosuppressive agents, graft-versus-host disease (GVHD) and opportunistic infections. TA-TMA has an unfavorable prognosis and responds poorly to conventional treatment including plasma exchange (PE). We present a case of a 37-year-old man with membranous nephropathy (MN) and Polyserositis caused by GVHD after hematopoietic stem cell transplantation. He developed TA-TMA after steroid pulse therapy for Polyserositis. We treated the patient with PE and mycophenolate mofetil (MMF) after which the TA-TMA successfully improved and the MN underwent complete remission. The present case suggests that corticosteroids with severe GVHD might increase the risk of TA-TMA, and that PE in combination with MMF may be a valuable therapy to improve the prognosis.
Guowang Yang - One of the best experts on this subject based on the ideXlab platform.
-
Pseudo-pseudo Meigs' syndrome presenting with a combination of Polyserositis, elevated serum CA 125 in systemic lupus erythematosus: A case report.
Medicine, 2019Co-Authors: Fei Gao, Guowang YangAbstract:AbstractRationale:Combination of Polyserositis and elevated serum CA 125 is common in tumor or infectious disease, but this clinical combination is also found in other diseases. It could be the initial manifestation of pseudo-pseudo Meigs’ syndrome (PPMS), which is characterized by the presence of p
Carol M. Richman - One of the best experts on this subject based on the ideXlab platform.
-
Filgrastim Treatment of Acute Myelogenous Leukemia (M7) Relapse after Allogeneic Peripheral Stem Cell Transplantation Resulting in Both Graft-versus-Leukemia Effect with Cytogenetic Remission and Chronic Graft-versus-Host Disease Manifesting as Polys
International journal of hematology, 2002Co-Authors: L.y. Law, Joseph Tuscano, Theodore Wun, K. Ahlberg, Carol M. RichmanAbstract:Filgrastim (granulocyte colony-stimulating factor) has recently been reported to successfully treat patients with leukemic relapse after allogeneic peripheral stem cell transplantation (PSCT). However, the majority of the patients who responded also developed graft-versus-host disease (GVHD). Polyserositis as a manifestation of GVHD is a rare phenomenon. We report the first case of Polyserositis following the use of filgrastim to treat a patient with acute myelogenous leukemia (M7), who had relapsed after an initially successful allogeneic PSCT. The Polyserositis manifested with effusions and was initially controlled with high doses of steroids and pericardial stripping; however, after a quiescent period the patient eventually developed bronchiolitis obliterans with organizing pneumonia that required additional immunosuppressive therapy. We review the literature on GVHD-associated Polyserositis and offer potential explanations for its pathogenesis.Int J Hematol. 2002; 76: 360-364.
Chanhee Chae - One of the best experts on this subject based on the ideXlab platform.
-
digoxigenin labeled in situ hybridization for the detection of streptococcus suis dna in Polyserositis and a comparison with biotinylated in situ hybridization
Journal of Veterinary Medical Science, 2014Co-Authors: Ikjae Kang, O H Yeonsu, Marcelo Gottschalk, Changhoon Park, Chanhee ChaeAbstract:The objective of this study was to develop digoxigenin-labeled in situ hybridization (ISH) for the detection of Streptococcus suis in naturally infected pigs with Polyserositis and to compare it with biotinylated ISH. Digoxigenin-labeled hybridization signals for S. suis were observed in cells that had infiltrated the fibrous Polyserositis and microcolonies in the blood vessels. Mock hybridization showed no hybridization signals for endogenous digoxigenin. Biotinylated hybridization signals for S. suis were observed in cells that had infiltrated the fibrous Polyserositis. However, similar hybridization signals were also observed in the fibrous inflammatory area using mock hybridization for endogenous biotin. The present study demonstrated that digoxigenin-labeled ISH is a valuable diagnostic tool for specific detection of S. suis in polyserositic tissues without nonspecific reactions compared with biotinylated ISH.
-
Optimized protocol for multiplex nested polymerase chain reaction to detect and differentiate Haemophilus parasuis, Streptococcus suis, and Mycoplasma hyorhinis in formalin-fixed, paraffin-embedded tissues from pigs with Polyserositis
Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, 2012Co-Authors: Ikjae Kang, Marcelo Gottschalk, Changhoon Park, Kiwon Han, Duyeol Kim, Jeehoon Lee, Hwi Won Seo, Chanhee ChaeAbstract:An optimized protocol was developed for the simultaneous detection and differentiation of Haemophilus parasuis, Streptococcus suis, and Mycoplasma hyorhinis in formalin-fixed, paraffin-embedded (FFPE) tissues with multiplex nested polymerase chain reaction (PCR). This method also determines the prevalence of these bacteria in pigs with Polyserositis. DNA extraction with a combination of a commercial reagent and proteinase K resulted in more frequent detection of the pathogens than DNA extraction with proteinase K alone. Among FFPE tissue samples from 312 cases of Polyserositis in which at least 1 bacterial species was detected, multiplex nested PCR detected H. parasuis in 239 (77%), S. suis in 124 (40%), and M. hyorhinis in 40 (13%). The disease was caused by a single pathogen in 224 (72%) of the cases and multiple pathogens in 88 (28%). Among the pigs positive for H. parasuis, S. suis, and M. hyorhinis by multiplex nested PCR, the pathogen was isolated from only 11%, 35%, and 28%, respectively. Therefore, the PCR protocol developed in this study is a useful diagnostic method when samples are negative after isolation methods and even for samples in which only 1 pathogen was isolated.
-
Development of In Situ Hybridization for the Detection of Mycoplasma hyorhinis in Formalin-Fixed Paraffin-Embedded Tissues from Naturally Infected Pigs with Polyserositis
The Journal of veterinary medical science, 2010Co-Authors: Bongtae Kim, Ikjae Kang, Kichan Lee, Kiwon Han, Duyeol Kim, Chung Hyun Kim, Jeehoon Lee, Chanhee ChaeAbstract:The aim of this study was to develop in situ hybridization for detection of Mycoplasma hyorhinis in formalin-fixed, paraffin-wax-embedded tissues from pigs with Polyserositis. M. hyorhinis was isolated from the spleen (2 pigs) and pericardium (1 pig). M. hyorhinis DNA was detected 16 out of 20 pigs with Polyserositis. In situ hybridization produced a distinct positive signal for the M. hyorhinis p37 gene in inflammatory cells in the Polyserositis. In situ hybridization developed in the present study present diagnostic tools capable of detection of M. hyorhinis in formalin-fixed, paraffin-wax-embedded tissues from the naturally infected pigs.
Jeremy Kroll - One of the best experts on this subject based on the ideXlab platform.
-
Duration of immunity for an inactivated Mycoplasma hyorhinis vaccine in pigs.
Veterinary microbiology, 2019Co-Authors: Brian Thomas Martinson, Whitney Zoghby, Kenneth Barrett, Lawrence Bryson, Jeremy KrollAbstract:Mycoplasma hyorhinis (Mhr) is a pathogen of pigs causing Polyserositis and polyarthritis. The most susceptible population are nursery pigs of approximately 7 weeks of age, although we have shown that clinical signs can persist into finishing aged animals after a late-nursery infection. We have previously demonstrated the efficacy of a novel inactivated Mhr vaccine for the reduction of lameness and Polyserositis in caesarian-derived colostrum-deprived (CDCD) pigs vaccinated at 3 weeks and challenged with Mhr at 6 weeks of age. Here we evaluated the duration of immunity (DOI) of the same vaccine. Vaccine or placebo was administered to CDCD pigs at 3 weeks of age. Pigs were challenged with Mhr at either 10 weeks of age (=7 week DOI) or 13 weeks of age (=10 week DOI). In the 7 week DOI, vaccination provided significant reductions in lameness (p = 0.0018), arthritis (p = 0.0002), and pericarditis (p = 0.0312) versus the placebo control. In the 10 week DOI, a significant reduction in arthritis (p = 0.0320) was observed in the vaccine group as compared to the placebo group. Both vaccine groups showed a significant increase (p
-
efficacy of an inactivated mycoplasma hyorhinis vaccine in pigs
Vaccine, 2018Co-Authors: Brian Thomas Martinson, Whitney Zoghby, Kenneth Barrett, Lawrence Bryson, Rodney Christmas, F.c. Minion, Jeremy KrollAbstract:Lameness and Polyserositis in pigs caused by Mycoplasma hyorhinis are generally treated with antibiotics and may require multiple doses. The costs of these antibiotics combined with economic losses from culling and reduced feed conversion due to lameness are hardships to the swine producer. In this study we have demonstrated efficacy of an inactivated M. hyorhinis vaccine administered to three-week old caesarian-derived colostrum-deprived piglets. Three doses of vaccine (high, medium, and low) were evaluated and compared to a placebo control. Mycoplasma hyorhinis challenge occurred three weeks after vaccination. Pigs were observed for lameness and respiratory distress for three weeks following challenge. Pigs were then euthanized and a gross pathological evaluation for Polyserositis and arthritis was performed. A minimum immunizing dose of vaccine was defined as containing at least 7.41 × 107 CCU of M. hyorhinis per 2.0 mL dose as represented by the medium dose vaccine. This vaccine provided significant reductions in lameness and pericarditis with preventive fractions of 0.76 (95% CI [0.26, 0.92]) and 0.58 (95% CI [0.31, 0.74]), respectively, compared to the placebo control group. A significant increase in post-challenge weight gain (P < .0001) was also achieved with this vaccine, with an average daily gain (ADG) of 0.92 lbs/day compared to 0.57 lbs/day in the placebo group.
-
Efficacy of an inactivated Mycoplasma hyorhinis vaccine in pigs.
Vaccine, 2017Co-Authors: Brian Thomas Martinson, Whitney Zoghby, Kenneth Barrett, Lawrence Bryson, Rodney Christmas, F.c. Minion, Jeremy KrollAbstract:Lameness and Polyserositis in pigs caused by Mycoplasma hyorhinis are generally treated with antibiotics and may require multiple doses. The costs of these antibiotics combined with economic losses from culling and reduced feed conversion due to lameness are hardships to the swine producer. In this study we have demonstrated efficacy of an inactivated M. hyorhinis vaccine administered to three-week old caesarian-derived colostrum-deprived piglets. Three doses of vaccine (high, medium, and low) were evaluated and compared to a placebo control. Mycoplasma hyorhinis challenge occurred three weeks after vaccination. Pigs were observed for lameness and respiratory distress for three weeks following challenge. Pigs were then euthanized and a gross pathological evaluation for Polyserositis and arthritis was performed. A minimum immunizing dose of vaccine was defined as containing at least 7.41 × 107 CCU of M. hyorhinis per 2.0 mL dose as represented by the medium dose vaccine. This vaccine provided significant reductions in lameness and pericarditis with preventive fractions of 0.76 (95% CI [0.26, 0.92]) and 0.58 (95% CI [0.31, 0.74]), respectively, compared to the placebo control group. A significant increase in post-challenge weight gain (P